Minor cannabinoids to be studied as part of NIH epilepsy programme

Minor cannabinoids to be studied as part of NIH epilepsy programme
Cannabis Health News

A Canadian cannabis company is set to study minor cannabinoids for the treatment of epilepsy as part of a National Institute of Health (NIH) programme. Cannabis research company, Cannabis Orchards, has signed an agreement with the National Institute of Health (NIH) to participate in the Epilepsy Therapy Screening Program (ETSP) to study minor cannabinoids, including CBGA and CBC. The NIH programme was designed to facilitate the discovery of new therapeutics that address the unmet medical needs in epilepsy. Almost all common epilepsy drugs have been included in the ETSP programme, including cannabidiol (CBD). The programme involves studying compounds in various preclinical models of epilepsy to determine the safety and efficacy of new candidate drugs for use as novel treatments.  Following completion of the qualifying process, Cannabis Orchards was chosen to submit minor cannabinoids, including cannabigerolic acid (CBGA) and cannabichromene (CBC), for inclusion in the programme. Cannabis Orchards is a research-driven Canadian biotechnology company focused on furthering the development and commercialisation of novel cannabinoids and therapeutics.  The use of minor cannabinoids as an anti-seizure drug was subject to a patent submission made by the company in September 2022. CEO, Dr Jamie Ghossein, commented: “After engaging in a rigorous qualifying process, we are proud to have been selected to register minor cannabinoids, namely CBGA and CBC, for inclusion in this world-renowned program. Minor cannabinoids will now be studied in the same way as common anti-seizure drugs as new alternatives for epilepsy treatment. “Minor cannabinoids have demonstrated promise as alternatives to anti-seizure drugs for epilepsy treatment, including CBD. With differing efficacy and side effect profile, minor cannabinoids may prove effective as anti-seizure medications for chronic use with enhanced tolerability compared to standard therapies.” Currently, the CBD-based Epidyolex, is the only FDA-approved cannabinoid treatment for drug-resistant epilepsy. With a market size expected to reach…

Excerpt only …
Source : Minor cannabinoids to be studied as part of NIH epilepsy programme

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.